Anebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for acute cannabinoid intoxication (“ACI”) and substance addiction, appointed Sandra Gardiner as the company’s acting chief financial officer.  Gardiner joins Anebulo from Pulse Biosciences, Inc., where she served as chief financial officer until December 2022.  She brings more than 30 years of financial, operational and management experience, with demonstrated leadership and...